Last mentioned: Mar 4, 2026
Aesthetic Market Realignment
Dermal filler and plastic surgery volumes hit record highs as patients seek to correct skin laxity post-weight loss.
Telehealth Pivot
Major digital health platforms launch dedicated GLP-1 programs with compounded options to address shortages.
The 'Ozempic Face' Viral Trend
Social media and news outlets begin highlighting the aesthetic side effects of rapid weight loss.
Wegovy Launch
FDA approves semaglutide specifically for chronic weight management, sparking mainstream interest.
Ozempic Approval
FDA approves semaglutide for Type 2 diabetes, marking the start of the GLP-1 era.
The rapid adoption of GLP-1 medications is triggering a seismic shift in American beauty standards and the aesthetic medicine market. Beyond weight loss, these drugs are driving a secondary boom in corrective cosmetic procedures and reshaping the business models of telehealth providers.